Lead-in protocol ID number | Study design | Patient population | Total patients in lead-in study, N | Patients included in ROP Study, n (%) |
---|---|---|---|---|
BO16216 | Anastrozole ± H | Breast cancer | 208 | 4 (16.0) |
BO18255 | H + cisplatin + FU or X | Gastric cancer | 594 | 6 (24.0) |
H0648g | H + AC or pac | Breast cancer | 469 | 1 (4.0) |
H0649g | H monotherapy | Breast cancer | 222 | 1 (4.0) |
M77001 | H + T | Breast cancer | 188 | 2 (8.0) |
M77003 | H + EC | Breast cancer | 120 | 6 (24.0) |
MO16419 | H + T + X | Breast cancer | 225 | 3 (12.0) |
WO16229 | H monotherapy | Breast cancer | 105 | 1 (4.0) |
WO17229 | H + T or pac | Breast cancer | 46 | 1 (4.0) |